Here, we present a protocol to isolate and culture rat endometrial epithelial stem cells (reESCs), generating rat endometrial organoids. This method facilitates in vitro studies of endometrial diseases, enabling gene editing and other cellular manipulations.
Endometrial organoids offer valuable insights into the development and pathophysiology of endometrial diseases and serve as platforms for drug testing. While human and mouse endometrial organoids have been developed, research on rat endometrial organoids remains limited. Given that rats can better simulate certain endometrial pathologies, such as intrauterine adhesions, this study aimed to establish rat endometrial organoids. We present a detailed protocol for the isolation and culture of rat endometrial epithelial stem cells (reESCs) and the generation of rat endometrial organoids. Using a refined reESCs expansion medium, we successfully isolated and stably expanded reESCs, demonstrating their long-term culture potential. The reESC-generated organoids exhibited typical structural and functional characteristics of the endometrium, including hormone responsiveness. Our results showed that rat endometrial organoids could be cultured over a long term with stable proliferation, maintaining the glandular structure, cell polarity, and functional characteristics of the endometrial epithelium. This novel rat-derived endometrial organoid model provides a valuable platform for studying endometrial diseases and testing therapeutic interventions, with potential applications across various mammalian species.
The endometrium, a versatile and regenerative tissue in the human body, undergoes periodic shedding, regeneration, and differentiation under the influence of ovarian hormones1. Abnormalities in the endometrium are linked to various female reproductive system diseases, such as endometriosis, endometrial cancer, and infertility2. The lack of reliable research models for the endometrium hampers in-depth studies of the pathogenesis, clinical diagnosis, and treatment of these diseases. While cell lines and animal models are commonly utilized for endometrial research, challenges such as phenotypic instability in cell lines, interspecies differences in animal models, and other limitations make it difficult to replicate the complex physiological structure and dynamic functional changes in the human endometrium3.
Organoids are three-dimensional structures formed by culturing stem cells in an extracellular environment, possessing self-renewal and self-organization capabilities. They can mimic the structure and function of physiological and pathological tissues and are recognized as preclinical models of human diseases4. In 2017, successful construction of mouse and human endometrial organoids was achieved by embedding fragmented free endometrial tissue obtained through enzymatic digestion into an extracellular matrix scaffold, followed by adding a mixture of specific growth factors and signaling factors for cultivation5. The results demonstrated that ex vivo endometrial organoids exhibit long-term and stable proliferative capacity, maintaining the glandular structure, cell polarity, and functional characteristics of the endometrial epithelium, including mucus secretion and hormone response6. However, the ex vivo culture of adult stem cells forming the endometrial organoids requires gland-like structural support, leading to challenges such as loss of stemness and difficulties in passaging7.
Currently, the cultivation of endometrial organoids relies on the tissue block digestion culture method. In a previous study, our research team cultured human endometrial epithelial stem cells for an extended period in vitro using a primary culture medium primarily composed of Y27632, which we employed to construct endometrial organoids8. Building on this success, we isolated and cultured endometrial epithelial stem cells from rat endometrial tissue using a small molecule compound culture medium, establishing a long-term in vitro culture system. Furthermore, we utilized rat endometrial epithelial stem cells (reESCs) to generate rat endometrial organoids. The development of this model will enhance future in vitro and in vivo studies of endometrial-related diseases in conjunction with rat models.
Six 7/8-week-old female Sprague-Dawley rats weighing 200-250 g were used in this work. The rats were housed in a climate-controlled animal facility with ad libitum access to food and water. All experimental procedures involving animals were conducted in adherence to the Institutional Guidelines for the Care and Use of Laboratory Animals and were approved by the institutional review board for animal experiments at the Research Ethics Committee of the Meizhou People's Hospital.
The following section outlines the process for isolating, passaging, freezing, and thawing rat endometrial epithelial stem cells using a refined reESCs expansion medium (REEM) comprised mainly of Y27632, A8301, and CHIR9902178,9. The REEM formulation is based on serum-free DMEM/F12 enriched with specific concentrations of key components: 10 µM Y27632, 3 µM CHIR99021, and 0.5 µM A8301. Comprehensive details regarding the components can be found in the Table of Materials. Once the rats have been anesthetized with isoflurane inhalation, the subsequent procedures depicted in Figure 1 should be implemented.
1. Surgical procedure
2. Tissue processing
3. Long-term culture of rat endometrial epithelial stem cells
4. Establishing rat endometrial organoids from reESCs
5. Long-term culture of rat endometrial organoids
6. Optional: Transitioning organoids to adherent culture
NOTE: The protocol mentions an alternative method for obtaining flat-cultured reESCs by transitioning organoids to adherent culture, allowing for the restructuring of organoid morphology.
7. Sequential culturing of organoids with estradiol (E2) and progesterone (P4)
The reESCs and rat uterus organoids were established from six female Sprague-Dawley rats weighing between 200 g and 250 g following the protocol outlined in Figure 1. Drawing on the success of the long-term culture of human endometrial epithelial stem cells, the REEM formulation predominantly consisted of Y27632, A8301, and CHIR99021. To stabilize the reESCs in vitro, we initially isolated endometrial cells from rat endometrium using enzymatic and mechanical techniques. Flow cytometry analysis in Figure 2A revealed that the primary endometrial cells comprised approximately 50% epithelial cells expressing CD9 (49.8%), with low levels of EpCAM (4.49%) and CD24 (2.64%). The SSEA-1 marker for reESCs was present at 6.58%, while endothelial markers CD31 (30.9%) and CD45 (70.3%) were relatively high.
However, culturing in REEM resulted in P1 reESCs displaying a uniform whorled or polyhedral morphology and forming compact clone structures (Figure 2D). Gradual removal of individual factors from REEM led to a corresponding decrease in the proliferative capacity of reESCs. The clone formation assay highlighted the critical role of Y27632 in the stable culture of reESCs (Figure 2B,C). By the third passage, reESCs exhibited consistent expression of SSEA-1 and Cytokeratin, indicating successful expansion of primary reESCs during culture (Figure 2F). Moreover, reESCs maintained robust and stable proliferative capacity even at late passages (Figure 2E), demonstrating their successful isolation and expansion in the current REEM system.
Organoid cultures were established following a previously reported system derived from human endometrial stem cells8. Within 3 days, the reESCs exhibited rapid self-organization into organoid-like structures with a hollow center, which subsequently increased in size and thickness (see Figure 3A). The typical HE staining results illustrating the formation of organoids by reESCs are presented in Figure 3B. These organoid cultures can be sustained through passaging, as evidenced by the high cell viability indicated by Ki67 staining following both direct passaging and freeze-thaw cycles. Furthermore, HE staining was performed on the 10th generation of organoids, and the results showed that the organoid structure could be maintained intact (see Figure 3E). Additionally, qPCR results indicated that Nanog, Sox2, and Oct4 were expressed at levels comparable to those of the P1 generation (Figure 3F). This finding suggests the potential for long-term culture of organoids within the current system.
Our study conducted a preliminary investigation into the response of rat uterine-like structures to E2 and P4. Immunofluorescence staining in Figure 4A revealed the presence of estrogen and progesterone receptors. Following E2 supplementation, these organoids underwent a transition from a hollow spherical form to a more densely populated internal growth pattern (Figure 4C). Subsequent exposure to P4 led to decreased permeability of the dense structures, ultimately resulting in their disintegration (Figure 4B). These findings suggest that E2 potentially drives further differentiation of rat uterine-like structures, whereas P4 may trigger apoptotic pathways.
Figure 1: Procedures used to establish rat endometrial epithelial stem cells and rat uterus organoids. Abbreviation: SD = Sprague-Dawley. Please click here to view a larger version of this figure.
Figure 2: Generation and long-term culture of rat endometrial epithelial stem cells in vitro. (A) Flow cytometric analysis showing the proportion of positive cells in the rat endometrium. (B) Crystal violet staining of clones in REEM with or without A8301, Y27632, or CHIR99021, respectively. Scale bars = 1 cm. (C) The clone numbers in REEM with or without factors. Error bars represent standard deviation; n = 3 donors (***, p<0.001). (D) Light microscopy images of P1 rat endometrial epithelial stem cells with and without crystal violet staining. (E) CCK-8 analyses of rat endometrial epithelial stem cells at passage 1, passage 7, and passage 14. Error bars represent standard deviation, n = 3. (F) Immunofluorescence analyses demonstrating the expression of Cytokeratin and SSEA-1. Abbreviation: REEM = reESCs expansion medium. Please click here to view a larger version of this figure.
Figure 3: Generation and long-term culture of rat endometrial organoids in vitro. (A) Light microscopy images of P1 rat endometrial organoids. (B) H&E staining for P1 organoids from rat endometrial epithelial stem cells. (C) Immunofluorescence analyses demonstrating the expression of Cytokeratin and SSEA-1. (D) Immunofluorescence analyses demonstrating the expression of Ki67 and SSEA-1. (E) H&E staining for P 10 rat organoids. (F) qPCR analyses for the expression of Nanog, Sox2 and Oct-4 in P1 and P10 rat endometrial organoids. Expression normalized to GAPDH (n = 3, two-tailed unpaired t-test, n.s. = non-significant). Abbreviation: H&E = hematoxylin and eosin. Please click here to view a larger version of this figure.
Figure 4: Sequential culturing of organoids with E2 and P4. (A) Immunofluorescence analyses demonstrating the expression of estrogen receptor, progestogen receptor, and SSEA-1. (B) Overview of light microscopy images of rat organoids cultured in E2 and P4. (C) Light microscopy images demonstrate the transformation of a hollow sphere into dense within the inner cavity of organoids after being cultured 7 days in E2. Abbreviations: ER = estrogen receptor; PR = progestogen receptor. Please click here to view a larger version of this figure.
In this study, we have described a straightforward method for isolating and culturing rat endometrial epithelial stem cells (reESCs) and refined the previously established ex vivo system for human endometrial epithelial stem cells8. Our approach utilizes a small molecule culture medium containing Y27632, A8301, and CHIR99021 as core components to enable stable and long-term ex vivo culture. Moreover, we successfully generated rat endometrial organoids in real time using reESCs. This novel system simplifies the current endometrial organoid culturing methods, which typically rely on tissue blocks, thereby providing greater clarity regarding cell lineage10. Importantly, our system facilitates gene editing and other manipulations at the cellular level to generate organoids expressing specific genes. Furthermore, this organoid system allows for the targeted knockout or overexpression of specific genes in rat endometrium, enabling the screening and cultivation of endometrial epithelial stem cells to produce endometrial organoids. This comprehensive research approach elucidates specific gene functions from both in vivo and ex vivo perspectives, paving the way for investigating diseases related to the endometrial epithelium.
Drug screening is a critical application of organoids. However, the current sources and preparation methods of organoids are complex, leading to significant variability between batches that can impact the outcomes of drug screening studies11,12. Our system demonstrates that organoids derived from stable ex vivo cultured cell lines can effectively minimize differences among formed organoids, enhancing uniformity in experimental setups. Furthermore, rat organoids formed by reESCs have demonstrated the ability to respond to estrogen stimulation in vitro, leading to morphological changes, suggesting that they can be used as a tool for drug screening ex vivo. The reESCs can be easily isolated from endometrial tissue and expanded ex vivo with fewer small molecules compared to human endometrial epithelial stem cells. This characteristic is particularly valuable for investigating stem cell properties, precursor cells, differentiation processes, and microenvironment interactions. Importantly, this approach can be extrapolated to other mammalian species such as monkeys, pigs, and dogs, enabling the establishment of endometrial organoid culture systems that serve as more physiologically relevant models for studying endometrial biology, function, diseases, and drug responses. Despite its advantages, this technique has limitations. One major limitation is the reliance on Matrigel, a complex and variable extracellular matrix that can introduce inconsistencies between experiments. Furthermore, while rat models provide valuable insights, interspecies differences still exist, and findings may not fully translate to human endometrial physiology and pathologies. Future studies should aim to address these limitations, potentially through the development of more defined and consistent extracellular matrices and by exploring the applicability of this model across other species.
Despite its advantages, this technique has limitations. One major limitation is the reliance on Matrigel, a complex and variable extracellular matrix that can introduce inconsistencies between experiments. Therefore, a key technique in this study is the removal of Matrigel. The use of a gentle matrix gel digestant, ensuring operations on ice, and sufficient digestion time are critical for success. Due to the larger diameter of the Pasteur pipette, using Pasteur pipette aspiration can reduce damage to organoids and accelerate the digestion of the matrix gel. Subsequent research can compare different extracellular matrix gel culture methods to further optimize the culture and digestion systems of organoids. Future studies should aim to address these limitations, potentially through the development of more defined and consistent extracellular matrices and by exploring the applicability of this model across other species.
While existing literature has described techniques for ex vivo culturing of epithelial organoids, this study presents a novel, straightforward, and readily reproducible system for cultivating and expanding rat endometrial organoids sourced from clear cells. This advancement is poised to enhance the pace of research in the realm of women's reproductive biology.
The authors have no conflicts of interest to declare.
This work was supported by GuangDong Basic and Applied Basic Research Foundation (2023A1515110760).
Name | Company | Catalog Number | Comments |
Anti-CD15 (SSEA-1) | Abcam | ab135377 | Rabbit, 1:200 (IHC) |
Anti-Estrogen Receptor alpha | Abcam | ab32063 | Rabbit, 1:200 (IHC) |
Anti-pan Cytokeratin | Abcam | ab7753 | Mouse, 1:250 (IHC) |
Anti-Progesterone Receptor | Abcam | ab101688 | Rabbit, 1:200 (IHC) |
Anti-Ki67 | Abcam | ab279653 | Mouse, 1:250 (IHC) |
A8301 | TargetMol | 909910-43-6 | |
β-Estradiol | Merck | E8875 | |
Cell Counting Kit-8 | Beyotime | C0038 | |
CD9 | BioLegend | 109819 | 1:20 (FC), Pacific Blue |
CD24 | BioLegend | 101806 | 1:20 (FC), FITC |
CD31 | BioLegend | 303120 | 1:20 (FC), APC |
CD45 | BioLegend | 301703 | 1:20 (FC), PE |
CHIR99021 | TargetMol | CT99021 | |
Cultrex Organoid Harvesting Solution | R&D Systems | 3700-100-01 | |
Cy3 TSA Fluorescence System Kit | APExBIO | K1051 | |
Cy5 TSA Fluorescence System Kit | APExBIO | K1052 | |
DAPI | Sigma | D9542 | 1 μg/mL |
DMEM/F-12 | Invitrogen | 11330032 | |
EpCAM | BioLegend | 369803 | 1:20 (FC), PerCP |
Fluorescein TSA Fluorescence System Kit | APExBIO | K1050 | |
Goat anti-Rabbit IgG, Alexa Fluor 488 | Invitrogen | A-11008 | 1:500 |
Goat anti-Mouse IgG, Alexa Fluor 555 | Invitrogen | A-21422 | 1:500 |
Goat Anti-rabbit IgG/HRP antibody | APExBIO | bs-0295G-HRP | |
Knockout serum replacement | Invitrogen | 10828028 | |
Matrigel | Corning | 356234 | |
PrimeScript RT Master Mix | Takara | RR063A | |
Progesterone | Merck | 57-83-0 | |
Sprague-Dawley rat | Shanghai JieSiJie Laboratory Animals Co., LTD, China | ||
SSEA-1 | BioLegend | 323047 | 1:20 (FC), APC |
TB Green Fast qPCR Mix | Takara | RR820A | |
TriZOL | Invitrogen | 15596026CN | RNA extraction |
u-Slide 8-well plates | Ibidi | 80827 | |
Y27632 | TargetMol | 146986-50-7 | |
qPCR primers of target genes | |||
Genes | Company | Sequences | |
rat GAPDH F | Sangon biotech | GACATGCCGCCTGGAGAAAC | |
rat GAPDH R | Sangon biotech | AGCCCAGGATGCCCTTTAGT | |
rat Nanog F | Sangon biotech | GACTAGCAACGGCCTGACTCA | |
rat Nanog R | Sangon biotech | CTGCAATGGATGCTGGGATA | |
rat Sox2 F | Sangon biotech | ATTACCCGCAGCAAAATGAC | |
rat Sox2 R | Sangon biotech | ATCGCCCGGAGTCTAGTTCT | |
rat Oct4 F | Sangon biotech | CCCAGCGCCGTGAAGTTGGA | |
rat Oct4 R | Sangon biotech | ACCTTTCCAAAGAGAACGCCCA GG |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved